Insurance coverage is an important condition for a test to become more widely used. But increasing the number of people who can access a test is not the same as increasing the number who actually take it.
On September 14, Guardant Health announced that its Shield blood test for colorectal cancer had been included in an EviCore by Evernorth policy, effective January 1, 2027. This is a change in insurance coverage, not a report of improved detection performance in a new clinical trial. Guardant Health announcement ↗
That distinction matters when assessing the business. A healthcare provider must offer the test under an eligible insurance plan, the patient must take it, and the insurer must actually pay. There are several steps between a broader policy and revenue. A company's stated eligible population cannot simply be treated as a forecast of future test volumes.
Another point to follow is what happens after a positive result. Shield does not complete the diagnostic process with a blood draw alone; a positive result requires further evaluation by colonoscopy. Intended use and follow-up after a positive result ↗
If a blood draw helps people who have not previously been screened make it all the way to diagnosis, wider adoption of the test could have considerable value. Its medical value would look different, however, if it mainly replaces other screening methods among people already being screened, or if many people cannot proceed to follow-up testing after a positive result. Rising test volumes alone cannot tell us this.
This card will track the policy's effective date, actual test volumes and payments, participation by previously unscreened people, and completion of colonoscopy after a positive result as separate measures. Expanded coverage puts one condition for growth in place. The next thing to watch is how far that opportunity translates into diagnostic and business results.
tests / quarter (company-reported, approximate)
Two same-quarter observations a year apart; the path between them is unknown. This does not measure the effect of the September Carelon announcement. Ratio calculated from rounded disclosures.
Sources: Guardant Health ↗Evidence & reading
Public sources checked for this edition. Linked pages may subsequently change.
- Guardant Healthの発表 ↗investors.guardanthealth.com · checked 2026-09-23
READER DISCUSSION
What does this change for you?
A question, a different reading, or a source we should consider. A short comment is welcome.
Comments are public only after editorial review. Comments, likes and reports are for people aged 18 or older. Sign-in is required; you choose a public display name. Reviews are not continuous. Discussion rules
Loading discussion…
Also in this issue
Contents →Commercialization
What Scientific AI Companies Sell Next: Experimental Data, Labs, and Drug Discovery Assets
Experimental services, laboratory infrastructure and drug assets: three ways scientific AI businesses earn returns.
R&D Allocation
Who Will Build the Systems to Oversee Clinical AI?
Patient support, supervision, implementation and independent evaluation: the research roles funded by ADVOCATE.
Frontier Science
How Far Can Human Neural Tissue Compensate for Lost Function?
Beyond graft survival: what could the animals do, and what remained impaired? Comparisons with dopamine and inhibitory-cell graft studies.
Frontier Science
Can measuring brain function help us choose an antidepressant?
How far did brain imaging, behavior and clinical information take medication selection? What SMART-D leaves to test next.
Frontier Science
What Do New Cells Contribute to a Brain That Preserves Memories?
Distinguishing the preservation of memory from the ability to tell similar situations apart and learn anew.